GSK

GSK(GSK)

LONDON, United Kingdom
Pharmaceutical1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules, Vaccines, Biologics

GSK is a life sciences company focused on Small Molecules, Vaccines, Biologics.

VaccinesInfectious DiseaseHIV/AIDSOncologyImmunology
Funding Stage
PUBLIC
Employees
70,000
Open Jobs
702

Products & Portfolio (23)

27 discontinued products not shown

ABREVA
docosanol
LOE Approaching
TOPICAL · CREAM
cold sores/fever blisters on the facelips shortens healing timeduration of symptoms: tingling+3 more
2000
30
ADVAIR DISKUS 100/50
fluticasone propionate and salmeterol
LOE Approaching
INHALATION · POWDER
salmeterol. The mechanisms of action described below for the individual components apply to ADVAIR DISKUS. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Inflammation is also a component in the pathogenesis of COPD. In contrast to asthma, however, the predominant inflammatory cells in COPD include neutrophils, CD8+ T-lymphocytes, and macrophages. The effects of corticosteroids in the treatment of COPD are not well defined and ICS and fluticasone propionate when used apart from ADVAIR DISKUS are not indicated for the treatment of COPD. Salmeterol Xinafoate Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta 2 -agonists may have cardiac effects. The pharmacologic effects of beta 2 -adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D 2 , from human lung. Salmeterol inhibits histamine-induced plasma protein extr
exacerbations of COPD in patients with a history of exacerbationsasthmachronic obstructive pulmonary disease+1 more
2000
30
ADVAIR DISKUS 250/50
fluticasone propionate and salmeterol
LOE Approaching
INHALATION · POWDER
salmeterol. The mechanisms of action described below for the individual components apply to ADVAIR DISKUS. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Inflammation is also a component in the pathogenesis of COPD. In contrast to asthma, however, the predominant inflammatory cells in COPD include neutrophils, CD8+ T-lymphocytes, and macrophages. The effects of corticosteroids in the treatment of COPD are not well defined and ICS and fluticasone propionate when used apart from ADVAIR DISKUS are not indicated for the treatment of COPD. Salmeterol Xinafoate Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta 2 -agonists may have cardiac effects. The pharmacologic effects of beta 2 -adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D 2 , from human lung. Salmeterol inhibits histamine-induced plasma protein extr
exacerbations of COPD in patients with a history of exacerbationsasthmachronic obstructive pulmonary disease+1 more
2000
30
ADVAIR DISKUS 500/50
fluticasone propionate and salmeterol
LOE Approaching
INHALATION · POWDER
salmeterol. The mechanisms of action described below for the individual components apply to ADVAIR DISKUS. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Inflammation is also a component in the pathogenesis of COPD. In contrast to asthma, however, the predominant inflammatory cells in COPD include neutrophils, CD8+ T-lymphocytes, and macrophages. The effects of corticosteroids in the treatment of COPD are not well defined and ICS and fluticasone propionate when used apart from ADVAIR DISKUS are not indicated for the treatment of COPD. Salmeterol Xinafoate Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta 2 -agonists may have cardiac effects. The pharmacologic effects of beta 2 -adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D 2 , from human lung. Salmeterol inhibits histamine-induced plasma protein extr
exacerbations of COPD in patients with a history of exacerbationsasthmachronic obstructive pulmonary disease+1 more
2000
30
ADVAIR HFA
fluticasone propionate and salmeterol xinafoate
LOE Approaching
INHALATION · AEROSOL, METERED
salmeterol. The mechanisms of action described below for the individual components apply to ADVAIR HFA. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices of asthma. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Salmeterol Xinafoate Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 ‑adrenoceptors than albuterol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta 2 -agonists may have cardiac effects. The pharmacologic effects of beta 2 -adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D 2 , from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor–induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness.
asthma in adultadolescent patients aged 12 yearsolder+1 more
2006
30
ADVIL
ibuprofen
LOE Approaching
SMORAL · TABLET
Cyclooxygenase Inhibitors
minor achespains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis temporarily reduces fever
1984
30
ADVIL
ibuprofen sodium
Peak
ORAL · TABLET
minor achespains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis temporarily reduces fever
2012
30
ADVIL ALLERGY AND CONGESTION RELIEF
chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride
Peak
ORAL · TABLET
Cyclooxygenase Inhibitors
2011
30
ADVIL ALLERGY SINUS
chlorpheniramine maleate, ibuprofen, pseudoephedrine hcl
LOE Approaching
ORAL · TABLET
Cyclooxygenase Inhibitors
these symptoms associated with hay feverother upper respiratory allergiesthe common cold: runny nose itchy+3 more
2002
25
ADVIL COLD AND SINUS
ibuprofen and pseudoephedrine hydrochloride
LOE Approaching
ORAL · TABLET
Cyclooxygenase Inhibitors
these symptoms associated with the common coldflu:
1989
30
ADVIL COLD AND SINUS
ibuprofen, pseudoephedrine hydrochloride
LOE Approaching
ORAL · CAPSULE
Cyclooxygenase Inhibitors
these symptoms associated with the common coldflu: headache fever sinus pressure nasal congestion minor body achespains
2002
30
ADVIL CONGESTION RELIEF
ibuprofen, phenylephrine hydrochloride
LOE Approaching
ORAL · TABLET
Cyclooxygenase Inhibitors
these symptoms associated with the common coldflu: headache fever sinus pressure nasal congestion minor body achespains reduces swelling of the nasal passages temporarily restores freer breathing through the nose
2010
30
View all 23 products

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT01858792A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
N/A
acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%
Acne Vulgaris
N/A
Clinical Trials (1)
NCT01446237U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
N/A
N/A
Clinical Trials (1)
NCT00931086Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99
N/A
Tazarotene Foam
Acne Vulgaris
Phase 1
Clinical Trials (1)
NCT01112787A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers
Phase 1
BLU-5937
Cough
Phase 1
Clinical Trials (1)
NCT03638180BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
Phase 1
Albaconozole
Onychomycosis
Phase 1
Clinical Trials (1)
NCT01014962A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus
Phase 1
Camlipixant
Cough
Phase 1
Clinical Trials (1)
NCT05959447Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
Phase 1
Phase 1
Clinical Trials (1)
NCT00509275A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)
Phase 1
Combination therapy GSK2894512 Cream A + GSK2894512 Cream B
Dermatitis, Atopic
Phase 1
Clinical Trials (1)
NCT02411162A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
Phase 1
Tazarotene Foam
Acne Vulgaris
Phase 1
Clinical Trials (1)
NCT01114841A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers
Phase 1
Clindamycin 1%-Benzoyl Peroxide
Acne Vulgaris
Phase 1
Clinical Trials (1)
NCT01132443W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne
Phase 1
S. sonnei 1790GAHB
Shigellosis
Phase 1
Clinical Trials (1)
NCT02034500Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
Phase 1
BLU-5937 IR
Cough
Phase 1
Clinical Trials (1)
NCT05570539Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
Phase 1
Phase 1
Clinical Trials (1)
NCT00938275A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT01340911A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases
Phase 1
Camlipixant
Cough
Phase 1
Clinical Trials (1)
NCT06222892A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
Phase 1
HGS1036 + Paclitaxel + Carboplatin
Cancer
Phase 1
Clinical Trials (1)
NCT01604863A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT01929278W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT01453491A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis
Phase 1
250 mg SRT2104 Suspension
Diabetes Mellitus, Type 2
Phase 1
Clinical Trials (1)
NCT00937872A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT00719121Study on Anti-inflammatory Effects of Topical R115866 Gel
Phase 1
Phase 1
Clinical Trials (1)
NCT06170827Study to Evaluate the AIO-001 in Healthy Participants
Phase 1
Cap SRT2104
Psoriasis
Phase 1
Clinical Trials (1)
NCT01702493A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT00920803A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases
Phase 1
Itraconazole
Healthy
Phase 1
Clinical Trials (1)
NCT00695071Study to Assess Blood Levels of Itraconazole During a Two-Week Period
Phase 1
[14C]-BLU-5937
Healthy
Phase 1
Clinical Trials (1)
NCT05244759Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
Phase 1
Tazarotene Foam without irradiation
Acne Vulgaris
Phase 1
Clinical Trials (1)
NCT01115322A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT02244489Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1
Albaconazole tablet 400mg
Onychomycosis
Phase 1
Clinical Trials (1)
NCT01039883A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
Phase 1
Tazarotene
Acne Vulgaris
Phase 1
Clinical Trials (1)
NCT01019603A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
Phase 1
S. sonnei 1790GAHB
Shigellosis
Phase 1
Clinical Trials (1)
NCT02017899A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
Phase 1
Phase 1
Clinical Trials (1)
NCT01031108A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus
Phase 1
Phase 1
Clinical Trials (1)
NCT00712855A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1
Phase 1
Clinical Trials (1)
NCT02258607Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
Phase 1
Tazarotene
Acne Vulgaris
Phase 1
Clinical Trials (1)
NCT01119651A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
Phase 1
BLU-5937
Healthy
Phase 1
Clinical Trials (1)
NCT06179537Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT05489237First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT00933530A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers
Phase 1
GSK2894512 cream
Psoriasis
Phase 1
Clinical Trials (1)
NCT01984775A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects
Phase 1
Camlipixant
Cough
Phase 1
Clinical Trials (1)
NCT05899829Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Phase 1
PNT2258
Cancer
Phase 1
Clinical Trials (1)
NCT01191775A Study of PNT2258 in Patients With Advanced Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT02206763Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1
SRT2379
Sepsis
Phase 1
Clinical Trials (1)
NCT01262911Effect of SRT2379 on Endotoxin-Induced Inflammation
Phase 1
SRT2379
Sepsis
Phase 1
Clinical Trials (1)
NCT01416376Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation
Phase 1
GSK5464714- Camlipixant
Cough
Phase 1
Clinical Trials (1)
NCT06497517A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
Phase 1
Phase 1/2
Clinical Trials (1)
NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01423058Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Phase 1/2
SRA737, gemcitabine, cisplatin
Advanced Solid Tumors
Phase 1/2
Clinical Trials (1)
NCT02797977A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT00935987Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02797964A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
Phase 1/2

Open Jobs (702)

Alternant - Ingénieur Génie Electrique H/F

France - Evreux
Yesterday

Global Procurement Manager Courier Category

UK – London – New Oxford Street
Yesterday

Territory Manager/Associate, Vaccines - Fraser Valley (18-month contract)

Canada – British Columbia – Vancouver
Yesterday

Customer Service Specialist (French speaking)

Poznan Grunwaldzka
Yesterday

Senior QA Executive - Validation (1.5 Years Contract)

Singapore - Tuas
Yesterday

Operations Technician

Singapore - Jurong
Yesterday

End to End Supply Chain Lead

UK – London – New Oxford Street
Yesterday
$135K - $226K/yr

Werksstudent (m/w/d) – Digital Transformation – Artificial intelligence

Dresden - Office
Yesterday

Regulatory Specialist-II -CTA/IND Development delivery

Bengaluru Luxor North Tower
Yesterday

Medical Director, Oncology Clinical Development

USA - Massachusetts - Waltham
Yesterday
$223K - $371K/yr

Senior Medical Manager- Hemato-oncology

India - Maharashtra - Worli Mumbai
Yesterday

Projects and Capital Lead

Pakistan - Sindh - Karachi
Yesterday

Internship: Gov Affairs, Market Access and Communication Trainee

Lisbon
Yesterday

Associate Director - Global Delivery Center - Procurement

Bengaluru Luxor North Tower
Yesterday

Stage Chef de Produit (H/F)

France - Rueil Malmaison
Yesterday

【今市】Facilities Maintenance Engineer (設備メンテナンスエンジニア)

Japan - Tochigi - Imaichi
Yesterday

Medical Advisor Oncology/Hematology

Field Worker - MAR
Yesterday

Előkészítő technikus

Hungary Gödöllő
Yesterday

First Line Sales Leader (Medan)

Indonesia - Sumatera Utara
Yesterday

General Worker

Pakistan - Sindh - Karachi
Yesterday

Assistant Manager Production

Pakistan - Sindh - Karachi
Yesterday

Sales Representative

Australia - NSW - Sydney Metro
Yesterday

Vaccine Business Manager (Jakarta)

Indonesia - DKI Jakarta
Yesterday

Production Supervisor/First Line Leader

USA - North Carolina - Zebulon
Yesterday

Manager, US Vaccine Policy

Washington F Street
Yesterday
$134K - $224K/yr
View all 702 open positions →
Interview Prep Quick Facts
Founded: 2001
Portfolio: 258 approved products, 150 clinical trials
Top TAs: Respiratory, Infectious Diseases, Oncology
H-1B (2023): 1 approval
Publications: 25 in PubMed
Open Roles: 702 active jobs
Portfolio Health
Pre-Launch37 (14%)
Launch3 (1%)
Growth2 (1%)
Peak33 (13%)
LOE Approaching156 (60%)
Post-LOE27 (10%)
258 total products
Therapeutic Area Focus
Respiratory
19 marketed738 pipeline
Infectious Diseases
27 marketed721 pipeline
Oncology
2 marketed658 pipeline
Neurology
21 marketed288 pipeline
Metabolic Diseases
1 marketed199 pipeline
Immunology
4 marketed165 pipeline
Cardiovascular
4 marketed140 pipeline
Gastroenterology
66 pipeline
Marketed
Pipeline

Hiring Trend

Actively Hiring
702
Open Roles
+736
Added
-20
Filled/Removed

Based on last 3 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub